Kate Nealon appointed Non Executive Director at Shire

27th Jul 2006 11:00

Kate Nealon appointed Non Executive Director at ShireBasingstoke, UK and Philadelphia, US -27 July, 2006 - The Board of Directors ofShire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that Kate Nealon willjoin as a Non Executive Director and a member of the Remuneration Committeewith immediate effect.Kate Nealon was Group Head of Legal & Compliance at Standard Chartered plcuntil 2003. She now holds Non Executive Director positions with HBOS plc, Cable& Wireless plc and Monitor, the independent regulator for NHS foundation trusthospitals in the UK. Ms Nealon is also a Senior Associate at the Judge BusinessSchool at Cambridge University.Ms Nealon is a lawyer and spent fifteen years in her early career practicinglaw in New York.A graduate of Georgetown University, Washington DC, Ms Nealon lives in London,UK.Dr James Cavanaugh, Chairman of Shire said:"Ms Nealon is an excellent addition to the Shire Board. Her internationalcareer brings significant experience of merger & acquisition activities, riskmanagement, compliance and regulatory issues with global companies."Kate Nealon said:"Shire is a very exciting and fast growing pharmaceutical company with animpressive pipeline and many opportunities ahead. I look forward to bringing myexperience to the Board and contributing towards helping the Company to achieveits global growth ambitions."For further information please contact:Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 SHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on attention deficit and hyperactivity disorder (ADHD),human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Thestructure is sufficiently flexible to allow Shire to target new therapeuticareas to the extent opportunities arise through acquisitions. Shire believesthat a carefully selected portfolio of products with a strategically alignedand relatively small-scale sales force will deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially affected. Therisks and uncertainties include, but are not limited to, risks associated with:the inherent uncertainty of pharmaceutical research, product development,manufacturing and commercialization; the impact of competitive products,including, but not limited to the impact of those on Shire's Attention Deficitand Hyperactivity Disorder (ADHD) franchise; patents, including but not limitedto, legal challenges relating to Shire's ADHD franchise; government regulationand approval, including but not limited to the expected product approval datesof SPD465 (ADHD), MESAVANCE (ulcerative colitis) and NRP104 (ADHD), includingits scheduling classification by the Drug Enforcement Administration in theUnited States; Shire's ability to benefit from the acquisition of TranskaryoticTherapies Inc.; Shire's ability to secure new products for commercializationand/or development; and other risks and uncertainties detailed from time totime in Shire's and its predecessor registrant Shire Pharmaceuticals Groupplc's filings with the Securities and Exchange Commission, including its AnnualReport on Form 10-K for the year ended December 31, 2005 and its most recentQuarterly Report filed on Form 10-Q for the financial period ended on March 31,2006. 1Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release FOR IMMEDIATE RELEASE Registered in England 2883758 Registered Office as aboveENDSHIRE PLC

---

Related Shares:

Shire